September 10, 2021 5:54pm

September 11th is tomorrow, bow your head and pray for the souls who lost their lives on this hallowed day

Pre-open indications: 2 HITs and 2 MISS

My comments try to distinguish the temporary from real pricing digression or progress with a 360-degree view.

Week in review …

Better visibility is needed into how things are going to look for the remainder of the year

The Dow closed DOWN -271.66 points (-0.78%); the S&P closed DOWN -34.70 points (-0.77%) while the Nasdaq closed DOWN -132.76 points (-0.87%)

 

Henry’omics:

For the holiday-shortened week, the Dow is down 12.2% and on pace for its second negative week in a row, the S&P 500 is off by 1.7% for the week, while the Nasdaq is -1.6% lower.

The major averages are still hovering around their all-time highs. The Dow is roughly 2.5% below its record, while the Nasdaq and S&P are about 1% from theirs

Sentiment also took a hit from Cleveland Federal Reserve Bank President Loretta Mester's comments that she would still like the central bank to begin tapering asset purchases this year despite the weak August jobs report. <Reuters>

 

Data Docket: The August producer prices index released Friday showed wholesale costs for businesses rose 8.3% on an annual basis, its biggest advance on record since at least 2010. The PPI accelerated 0.7% for the month, above the 0.6% Dow Jones estimate. The more important consumer price index for August will be released on Tuesday.

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Friday opened positive at 23/9, 2 flats and 1 acquired, flipped negative at the mid-day to 10/24 and 1 acquired, closing negative 7/26, 1 flat and 1 acquired;
  • Thursday opened positive at 20/13, 1 flat and 1 acquired, stayed positive at the mid-day to 24/10 and 1 acquired, closing positive 20/13, 1 flat and 1 acquired;
  • Wednesday opened negative at 9/24, 1 flat and 1 acquired, stayed negative at the mid-day to 10/24 and 1 acquired, closing negative 7/27 and 1 acquired;
  • Tuesday opened positive at 25/8, 1 flat and 1 acquired, flipped negative at the mid-day to 9/24, 1 flat and 1 acquired, closing negative 10/22, 2 flats and 1 acquired;
  • Monday was a holiday

 

RegMed Investors’ (RMi) pre-open: “following the bouncing share pricing” …  https://www.regmedinvestors.com/articles/12089

 

The Biostage (BSTG) Chronicles: “The Biostage (BSTG) Chronicles - Maintaining Sell - Is this another Theranos – faking it to not make it?” … https://www.regmedinvestors.com/articles/12087

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

  • Net Income: 3 and Net losses: 23

 

Key Metrics:

  • Sector volume was LOW with 1 of the 7-upside having higher than the 3-month average volume with very LOW volume of 3 of 26-downside having higher than the 3-month average volume;
  • Friday’s percentage (%) of the 7-upside were +0.44% (RARE) to +2.56% (EDIT) while the 26-downside -0.03% (ALNY) to -6.67% (GBT);

 

The Biostage (BSTG) Chronicles: Is at to its usual “pump/promote”, Friday closed down -$0.19 to $3.79 with 22,124 shares traded after Thursday traded up +$0.66 to $3.98 with 6,0622 shares traded after Wednesday traded +$0.57 with 7,833 shares traded, Tuesday closed down -$0.75 to $2.75 with 6,705 shares traded following Monday’s holiday

  • Today is just another fact, how the share trades with the “push/promote” - another typical example,
  • WHAT is BSTG’s value proposition, after all the share price “pumping”?

 

Pre-open Indications: 2 HITs < Maintaining SELL: Biostage (BSTG -$0.19), Editas Medicine (EDIT +$1.65)> 2 MISS < Intellia Therapeutics (NTLA -$0.14), CRISPR Therapeutics (CRSP -$0.72)>

 

There are clear winners and losers

Jumping with share pricing momentum:

  • Editas Medicine (EDIT), Sage Therapeutics (SAGE), Ultragenyx (RARE), MiMedx (MDXG), Mesoblast (MESO), Homology Medicine (FIXX), Bellicum Pharmaceuticals (BLCM), to name 7 of the 7 inclining of the 35 covered

Hammered in today’s market:

  • Vericel (VCEL), Global Blood Therapeutics (GBT), BioLife Solutions (BLFS), Fate Therapeutics (FATE), AxoGen (AXGN) to name 5 of the 26 declining of the 35 covered

 

Friday (7 of 7 incliners)

  • Editas Medicine (EDIT +$1.65 after Thursday’s +$0.13, Wednesday’s -$2.41 and Tuesday’s -$1.52);
  • Sage Therapeutics (SAGE +$0.61 after Thursday’s -$1.08);
  • Ultragenyx (RARE +$0.45 after Thursday’s -$1.06, Wednesday’s +$0.32 and Tuesday’s -$0.42);
  • MiMedx (MDXG +$0.18 after Thursday’s -$0.48, Wednesday’s +$0.15 and Tuesday’s +$0.12);
  • Mesoblast (MESO+$0.13 after Thursday’s -$0.41);
  • Homology Medicine (FIXX +$0.12);
  • Bellicum Pharmaceuticals (BLCM +$0.03 after Thursday’s -$0.03);

Friday’s (10 of 26) decliners:

  • Vericel VCEL -$2.98);
  • Global Blood therapeutics (GBT -$2.01);
  • BioLife Solutions (BLFS -$1.210;
  • Fate Therapeutics (FATR -$0.89);
  • AxoGen (AXGN -$0.86 after Thursday’s -$0.40, Wednesday’s +$0.01 and Tuesday’s +$0.27);
  • CRISPR Therapeutics (CRSP -$0.72 after Thursday’s +$2.20, Wednesday’s -$1.25 and Tuesday’s -$1.45);
  • Cellectis SA (CLLS -$0.61 after Thursday’s +$0.55 and Wednesday’s -$0.67);
  • Regenxbio (RGNX -$0.56 after Thursday’s +$0.16, Wednesday’s -$0.86 and Tuesday’s -$0.64);
  • ReNeuron (RENE.L -$0.50 after Thursday’s -4.00 and Wednesday’s -$1.50)
  • uniQure NV (QURE -$0.35 after Thursday’s +$0.78);

Closing –1 - Solid Biosciences (SLDB) - flat and 1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday, the IBB closed down -0.37% and XBI closed down -0.83%
  • Thursday, the IBB closed up +0.12% and XBI closed up +0.39%
  • Wednesday, the IBB closed up +0.96% and XBI closed down -1.16%
  • Tuesday, the IBB closed down -0.21% and XBI closed down -0.54%
  • Monday was a holiday

 

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was up +2.15 points or +11.44% at 20.95
  • Thursday was up +0.84 points or +4.68% at 18.80
  • Wednesday was down -0.18 points or -0.99% at 17.96
  • Tuesday was up +1.73 points or +10.54% at 18.14
  • Monday was a holiday

 

Upside volume:

  • Friday: 1 out of the 7-upside had higher than the 3-month average volume;
  • Thursday: 5 out of the 20-upside had higher than the 3-month average volume;
  • Wednesday: 1 out of the 7-upside had higher than the 3-month average volume;
  • Tuesday: 3 out of the 10-upside had higher than the 3-month average volume;
  • Monday was a holiday

 

Downside volume:

  • Friday: 3 out of the 26-downside had higher than the 3-month average volume;
  • Thursday: 2 out of the 13-downside had higher than the 3-month average volume;
  • Wednesday: 3 out of the 27-downside had higher than the 3-month average volume;
  • Tuesday: 4 out of the 22-downside had higher than the 3-month average volume;
  • Monday was a holiday

 

Percentage (%) movement/range statistics: price versus percentage …

  • Friday’s percentage (%) of the 7-upside were +0.44% (RARE) to +2.56% (EDIT) while the 26-downside -0.03% (ALNY) to -6.67% (GBT);
  • Thursday’s percentage (%) of the 20-upside were +0.19% (BLFS) to +19.88% (BSTG) while the 13-downside -0.29% (FATE) to -6.30% (MESO);
  • Wednesday’s percentage (%) of the 7-upside were +0.06% (AXGN) to +20.73% (BSTG) while the 27-downside -0.33% (PSTI) to -4.98% (FATE);
  • Tuesday’s percentage (%) of the 10-upside were +0.25% (FATE) to +12.31% (QURE) while the 22-downside -0.24% (BLFS) to -21.43% (BSTG);
  • Monday was a holiday

 

September, the third month of Q3/21:

Friday closed negative with 7 advancers, 26 decliners, 1 flat and 1 acquired

Thursday closed positive with 20 advancers, 13 decliners, 1 flat and 1 acquired

Wednesday closed negative with 7 advancers, 27 decliners and 1 acquired

Tuesday closed negative with 10 advancers, 22 decliners, 2 flats and 1 acquired

Monday was a holiday

 

The BOTTOM LINE: I haven’t had long to wait for my prediction of a bumpy September-October timeframe.

When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started.

Q2 reporting season has essentially run its course; although a few remain with my questions of WHY so late …?

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.